Soumaïla Camara1, Evariste Bouenizabila2, Michel P Hermans3, Sylvie A Ahn4, Michel F Rousseau4. 1. Ecole de Santé Publique, Faculté de Médecine, Université Libre de Bruxelles, Belgium. 2. Service de Maladies Métaboliques et Endocriniennes, Centre Hospitalier et Universitaire de Brazzaville, Congo. 3. Division of Endocrinology & Nutrition, Cliniques universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium. Electronic address: michel.hermans@diab.ucl.ac.be. 4. Division of Cardiology, Cliniques universitaires St-Luc and Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
Abstract
BACKGROUND: T2DM management requires tight control of 3 critical quality indicators to prevent vascular complications: LDL-C, SBP, and HbA1c. This study evaluated the rate of T2DM patients attaining these critical quality indicators, and the pathophysiological or cardiometabolic traits predicting goal achievement. PATIENTS AND METHODS: Cross-sectional analysis evaluating combined goal achievement (LDL-C<100 mg/dL; SBP<130 mmHg and HbA1c<7.0%) in 1005 T2DM outpatients (654 men) followed in a university hospital multidisciplinary department. Triple-goal achievers were compared to non-achievers regarding sociodemographics; anthropometrics; homeostatic model assessment (HOMA; β-cell function (B); insulin sensitivity (S); hyperbolic product (B×S)); CV and glucose-lowering drugs; micro-/macro-vascular outcomes; and 10-year UKPDS risk. RESULTS: Eighty-eight patients (9%; ((3 targets) group) reached all goals, whereas 917 patients (91%; ((0-2 target(s)) group) missed 1, 2 or all 3 goals. Compared to (0-2 target(s)), (3 targets) had shorter diabetes duration; less familial diabetes history; lower waist/visceral fat; higher β-cell function and hyperbolic product (B×S); lower (B×S) loss rate and less metabolic syndrome (all p<0.05). They had lower apoB and triglycerides; and a 28% prevalence of atherogenic dyslipidemia (vs. 40% in (0-2 target(s)); p 0.0398). Microangiopathy (36% vs. 53%) and 10-year CAD risk (13% vs. 18%) were also significantly lower in (3 targets). CONCLUSIONS: The subset of T2DM patients achieving all critical quality indicators are characterized by a less severe cardiometabolic phenotype, while exhibiting a less pronounced alteration of their residual β-cell function. These differences are related to fewer microvascular outcomes and lower 10-year CV risk.
BACKGROUND: T2DM management requires tight control of 3 critical quality indicators to prevent vascular complications: LDL-C, SBP, and HbA1c. This study evaluated the rate of T2DM patients attaining these critical quality indicators, and the pathophysiological or cardiometabolic traits predicting goal achievement. PATIENTS AND METHODS: Cross-sectional analysis evaluating combined goal achievement (LDL-C<100 mg/dL; SBP<130 mmHg and HbA1c<7.0%) in 1005 T2DM outpatients (654 men) followed in a university hospital multidisciplinary department. Triple-goal achievers were compared to non-achievers regarding sociodemographics; anthropometrics; homeostatic model assessment (HOMA; β-cell function (B); insulin sensitivity (S); hyperbolic product (B×S)); CV and glucose-lowering drugs; micro-/macro-vascular outcomes; and 10-year UKPDS risk. RESULTS: Eighty-eight patients (9%; ((3 targets) group) reached all goals, whereas 917 patients (91%; ((0-2 target(s)) group) missed 1, 2 or all 3 goals. Compared to (0-2 target(s)), (3 targets) had shorter diabetes duration; less familial diabetes history; lower waist/visceral fat; higher β-cell function and hyperbolic product (B×S); lower (B×S) loss rate and less metabolic syndrome (all p<0.05). They had lower apoB and triglycerides; and a 28% prevalence of atherogenic dyslipidemia (vs. 40% in (0-2 target(s)); p 0.0398). Microangiopathy (36% vs. 53%) and 10-year CAD risk (13% vs. 18%) were also significantly lower in (3 targets). CONCLUSIONS: The subset of T2DM patients achieving all critical quality indicators are characterized by a less severe cardiometabolic phenotype, while exhibiting a less pronounced alteration of their residual β-cell function. These differences are related to fewer microvascular outcomes and lower 10-year CV risk.
Authors: Matthieu Chodorge; Anthony J Celeste; Joseph Grimsby; Anish Konkar; Pia Davidsson; David Fairman; Lesley Jenkinson; Jacqueline Naylor; Nicholas White; Jonathan C Seaman; Karen Dickson; Benjamin Kemp; Jennifer Spooner; Emmanuel Rossy; David C Hornigold; James L Trevaskis; Nicholas J Bond; Timothy B London; Andrew Buchanan; Tristan Vaughan; Cristina M Rondinone; Jane K Osbourn Journal: Sci Rep Date: 2018-12-03 Impact factor: 4.379
Authors: Jorge Navarro-Pérez; Domingo Orozco-Beltran; Vicente Gil-Guillen; Vicente Pallares; Francisco Valls; Antonio Fernandez; Ana María Perez-Navarro; Carlos Sanchis; Alejandro Dominguez-Lucas; Jose M Martin-Moreno; Josep Redon; Maria Tellez-Plaza Journal: BMC Cardiovasc Disord Date: 2018-09-04 Impact factor: 2.298
Authors: Bashair K Alshahri; Manar Bamashmoos; Mona I Alnaimi; Shaykhah Alsayil; Shymaa Basaqer; Mohammed T Al-Hariri; Christopher Amalraj Vallaba Doss Journal: Cureus Date: 2020-12-05